Copy For Citation
Schmid P., Cortes J., Pusztai L., McArthur H., Kuemmel S., Bergh J., ...More
NEW ENGLAND JOURNAL OF MEDICINE, vol.382, no.9, pp.810-821, 2020 (SCI-Expanded)
-
Publication Type:
Article / Article
-
Volume:
382
Issue:
9
-
Publication Date:
2020
-
Doi Number:
10.1056/nejmoa1910549
-
Journal Name:
NEW ENGLAND JOURNAL OF MEDICINE
-
Journal Indexes:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
-
Page Numbers:
pp.810-821
-
Acibadem Mehmet Ali Aydinlar University Affiliated:
Yes
Abstract
Background Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear.